SCHEMBL3042332

SCHEMBL3042332

CC(=O)N1c2ccccc2-c2ccccc2C1CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 4/20 0.51
KDM4E B2RXH2 2/20 0.42
HIF1A Q16665 1/20 0.42
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
ALOX15 P16050 1/20 0.41
EGFR P00533 1/20 0.39
GAA P10253 1/20 0.39
GPR3 P46089 1/20 0.38
POLB P06746 1/20 0.38
BRD4 O60885 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
HTT P42858 1/20 0.38
NOTUM Q6P988 2/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38
CDC25A P30304 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3040022 0.85 KCNA3 (0.45) KCNA3KDM4EHIF1AHSD17B10ALDH1A1
SCHEMBL27676789 0.80 KCNA3 (0.46) KCNA3KDM4EHIF1AHSD17B10ALDH1A1
SCHEMBL3041687 0.79 ALDH1A1 (0.47) KCNA3KDM4EHSD17B10ALDH1A1GLA
SCHEMBL3045327 0.75 TACR1 (0.41) HSD17B10ATMTSHR
SCHEMBL3041470 0.75 CREBBP (0.50) KCNA3KDM4EHIF1AHSD17B10ALDH1A1
SCHEMBL12204834 0.73 BDKRB1 (0.44) ALDH1A1POLBMAPTATM
SCHEMBL2516752 0.71 BDKRB1 (0.54) KCNA3ALDH1A1GAAPOLBMAPT
SCHEMBL4468979 0.71 HTT (0.48) KDM4EALDH1A1POLBMAPTHTT
SCHEMBL68113 0.71 KDM4E (0.50) KDM4EHIF1AHSD17B10ALDH1A1GLA
SCHEMBL2516421 0.70 BDKRB1 (0.44) MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216772-A1 Novel Phenantridine Analogues and Uses Thereof 4SC AG (DE) 2010-08-26 US disclosed
US-7276606-B2 Phenantridine analogues and uses thereof 4SC AG (DE) 2007-10-02 US disclosed
EP-1740548-A1 NOVEL PHENANTRIDINE ANALOGUES AND THEIR USES AS INHIBITORS OF HYPERPROLIFERATION OF T CELLS AND/OR KERATINOCYTES 4SC AG (DE) 2007-01-10 EP disclosed
EP-1652841-A1 Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes Switch Biotech Aktiengesellschaft (DE) 2006-05-03 EP disclosed
US-20050282801-A1 Novel phenantridine analogues and uses thereof SWITCH BIOTECH AG (DE) 2005-12-22 US disclosed
WO-2005105752-A1 NOVEL PHENANTRIDINE ANALOGUES AND THEIR USES AS INHIBITORS OF HYPERPROLIFERATION OF T CELLS AND/OR KERATINOCYTES 4SC AG (DE) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216772-A1 Novel Phenantridine Analogues and Uses Thereof P2RX4, P2RX5, CLIC4 KCNA3 52/4885KDM4E 2178/4885HIF1A 2740/4885
US-20050282801-A1 Novel phenantridine analogues and uses thereof P2RX4, P2RX5, CLIC4 KCNA3 52/4885KDM4E 2178/4885HIF1A 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.